Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.

Abstract excerpt

Treatment with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1) can generate durable responses in various cancer types, but only in a subset of patients. The use of predictive biomarkers for response to PD-1/PD-L1 inhibitors is critical for patient selection. Expression of PD-L1 has demonstrated utility in patient selection. Tumour mutational burden (TMB) is an...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents, Immunological
• B7-H1 Antigen
• Biomarkers, Tumor
• Drug Resistance, Neoplasm
• Immunotherapy